Research into Huntington’s Disease is being driven forward by a £3.3m investment, in a project hailed as giving the first ‘realistic chance’ of finding treatments to slow down its progression.
The five-year study will help advance knowledge of disease mechanisms in HD and identify robust outcome measures for future disease-modifying clinical trials.
This ambitious project will advance current understanding of mechanisms underlying HD and exploit this knowledge for therapeutic development.
The work, funded by a Wellcome Trust Collaborative Award, will not only give hope to the HD community but will provide valuable insights into other neurodegenerative diseases.
“For the first time we have a realistic chance of finding treatments which actually slow down the disease process,” says Professor Sarah Tabrizi, principal investigator of the Wellcome Centre for Human Neuroimaging’s Huntington’s Disease team and director of UCL’s Huntington’s Disease Centre.
“Ideally we aim to administer the most successful therapies to gene carriers years before widespread damage has occurred, with the hope that we can prevent or at least significantly delay disease onset.”
This new project will probe disease mechanisms at the molecular, cellular and systems level and will investigate instability within the HD gene which is known to drive disease progression.
Mechanisms underlying the gene’s effect on molecular processes will be elucidated within cells and in mouse models of HD.
Ongoing collaborations with industrial partners, Roche and Ionis Pharmaceuticals, will allow assessment of the potential therapeutic benefit of drugs directly targeting these pathways.
The study is being led by researchers from UCL, the University of Cambridge and University of Glasgow.
While ongoing trials currently seek to modify the disease in symptomatic patients, the HD Centre’s HD Young Adult Study has shown that the earliest signs of neuronal damage occur up to 24 years before the expected onset of clinical symptoms; this is likely to be the optimum time to intervene with treatments to slow or halt disease progression.
It will use advanced imaging techniques including 7T and magnetoencephalography to examine brain structure and function in far-from-onset gene carriers.
Professor Michael Hanna, director of UCL Queen Square Institute of Neurology, adds: “I am delighted that Sarah and her colleagues have been awarded this important grant from the Wellcome Trust which fits perfectly with the translational neuroscience strategy of the ION and will fund fundamental mechanistic research into finding and testing prevention therapies for Huntington’s disease.”
Women ‘under-represented in stroke trials for 30 years’
‘Put policy into practice so future research can address gaps in the understanding and treatment of stroke in women’
Women have been under-represented in stroke clinical trials for the past 30 years, new research has found, making it harder to interpret what the findings really mean for them.
The study found that more than three quarters of the trials enrolled less women than the expected proportion that experience stroke in the community.
George Institute researchers looked at 281 stroke trials that had at least 100 participants and were conducted between 1990 and 2020.
The total number of participants was 588,887, of whom 37.4 per cent were women, but the average prevalence of stroke in women across the countries included was 48 per cent.
“It’s now time to put policy into practice so that future research can address our knowledge gaps in the understanding and treatment of stroke in women,” said study co-author Dr Katie Harris.
While there have been studies showing varying degrees of representation of women in cardiovascular trials, this issue has only recently started to be examined in relation to stroke trials.
The greatest differences were seen in trials involving a particular type of stroke known as intracerebral haemorrhage, those where the mean age of participants was less than 70.
Lead author Dr Cheryl Carcel, from The George Institute for Global Health and a Heart Foundation Fellow, said that while both women and men had the same one-in-four risk of experiencing a stroke in their lifetime, women were much older and in worse health at the time they have a stroke.
“These findings have implications for how women with stroke may be treated in the future, as women typically have worse functional outcomes after stroke and require more supportive care,” said Dr Carcel.
Dr Carcel said the reasons for this under-representation were complex and most likely due to a number of factors, including recruitment criteria that unintentionally exclude women like age and having other health conditions.
“Patient attitudes and beliefs can also be a factor, and there can even be a potential bias among the clinical staff conducting the study,” she said.
“Our previous research indicated that how women were treated in hospital and whether they had been on the right medications before their stroke, could be responsible for their poorer outcomes.”
Dr Harris said that barriers and facilitators to women’s participation in stroke trials needed to be explored both at the trial and patient level to help redress the balance.
“Achieving a better gender representation in stroke trials can provide a more reliable assessment of the treatment benefits and harms, and inform treatment guideline recommendations for women affected by this serious condition,” she said.
While the United States, Canada and some European countries, adopted policies to boost the number of women in clinical trials over the course of the study, the results showed no change over this time.
“Our study suggests those efforts have clearly not translated into action,” Dr Harris added.
‘Take urgent action on rugby player safety’
Rugby’s authorities must act now to protect players at all levels, following publication of the landmark BRAIN study
Rugby’s governing authorities are being urged to take “urgent preventative action” to protect players at all levels of the sport after new research suggests the game may have been safer in the pre-professional era.
The BRAIN study, published today, found that former elite rugby players who experienced three or more concussions during their career did not have worse cognitive function before the age of 75 than those who had experienced no, or just one or two, concussions.
The study found no overall group association between concussion history and worse cognitive function, but did find that 29 per cent of over 75s who had sustained three or more rugby-related concussions during their career had significantly worse cognitive function.
However, results from the BRAIN study – funded by The Drake Foundation, which worked with 146 former elite rugby players in England aged 50 and over, most of whom played in the pre-professional era – call into question whether safety standards in the sport have worsened since the game became professional.
Several retired players from the modern era have recently been diagnosed with early-onset neurodegenerative disease and likely Chronic Traumatic Encephalopathy (CTE).
In addition, the neuroimaging results of the Drake Rugby Biomarker Study, published earlier this year, found that 23 per cent of current elite adult rugby players tested had abnormalities in brain structure, and half showed an unexpected change in brain volume.
The Foundation has also been vocal in its campaign to make recommendations around safety in rugby and football enforceable rules, and is now calling for further immediate emphasis on player welfare.
“These findings are broadly reassuring for players from the amateur era,” says Lauren Pulling, CEO of The Drake Foundation.
“However, given the findings of the Drake Rugby Biomarker Study and recent cases of early-onset brain disease in ex-players from the professional era, the new study results do call into question how long-term health might differ in players from the modern era.
“The evidence we have so far suggests that the sport may actually be travelling in the wrong direction in terms of player welfare and brain health.
“In addition to further research, we therefore also urge the sport’s governing bodies to review the modern game’s laws and protocols and take urgent, preventative action to universally reduce players’ exposure to head impacts both in matches and training.”
Additional research carried out this month on behalf of The Drake Foundation by Censuswide, via an online survey of 508 respondents in the UK who are involved in rugby union, found that 62 per cent of adults who either play amateur rugby or have a child who plays rugby are concerned about the long-term effects of the sport on their or their child’s brain health.
This figure rises to 73 per cent for parents who do not play the game themselves, but who have a child that does.
Over 60 per cent agree that rugby has become a more dangerous sport at all levels since it turned professional in 1995, whilst 66 per cent believe that rugby union would be safer if fundamental law changes were introduced to better reflect the way the sport was played in the pre-professional era.
James Drake, founder of The Drake Foundation, says: “As a passionate sports fan who loves rugby, I’ve witnessed first-hand the way the game has evolved since turning professional.
“In my view it’s a sport that has become ostensibly less safe for the players involved and my concerns are reflected by our research this month, which reveals 61 per cent of adults who either play the game or have children that do, are concerned about the sport’s long-term effect on brain health.
“A further two thirds of adults believe the sport could be made safer if law changes were introduced to return it to the game as it was played in the amateur era. The Drake Foundation is calling on rugby’s authorities to give this immediate consideration to protect the sport we love and the current and future generations who play it.”
The BRAIN study is the first to carry out detailed measurements of cognitive function in a large number of former players and to relate this to their concussion and playing history.
It was conducted by the London School of Hygiene & Tropical Medicine, Queen Mary University of London and the Institute of Occupational Medicine with researchers from UCL and the University of Oxford, and with assistance from the Rugby Football Union (RFU).
It is also the first to include substantial numbers from the over-75 age-group. Previous studies which have focussed on younger players have found little or no association between concussions and reduced cognitive function.
Research reveals how brain cells talk
Breakthrough could help in the treatment of mental health and early-stage neurodegenerative diseases
New understanding of how brain cells talk could help in the treatment of mental health conditions and early-stage neurodegenerative diseases.
Researchers have discovered that reversing the modification of molecular messages at synapses in the human brain may contribute to conditions including anxiety and dementia.
The findings, published today, are hailed as a major step in our understanding of how brain cells communicate, and could help to identify new treatments for neurological and psychiatric conditions.
The research was led by Dr Helen Miranda Knight in the School of Life Sciences at the University of Nottingham, along with researchers across the Schools of Medicine, Life Science, and Bioscience.
She said: “The implications are very important for normal brain function but also for reversible psychiatric mental conditions such as anxiety and addiction disorders and early-stage neurodegenerative diseases such as dementias.”
Nerve cells in the human brain talk to each other at sites called synapses, where molecules are released to signal to the next cell.
When people learn or remember things, this signalling is strengthened. When communication between synapses goes wrong, circuits become broken.
As more circuits are lost, this changes how people can think and perform everyday tasks. This is seen in cognitive disorders, such as forms of dementia and some mental health conditions.
The function of nerve cells and synapses depends on proteins that are made using information encoded in genetic material called RNA. It is thought that RNAs are located exactly where and when they are needed for synaptic signalling because some kind of synaptic ‘tag’ labels the correct active synapse.
Scientists have recently learnt that RNA can have a methyl group or molecule added to one of the RNA bases which ‘marks’ the RNA message. Such adding of methyl groups can influence proteins binding to DNA or RNA and consequently stop proteins being produced.
This new study shows that RNA marking can be reversed at synapses and hence may act as a ‘synaptic tag’. The findings suggest, that if disrupted, this could cause synapses and nerve cells to malfunction by influencing the formation of toxic protein clumps.
The researchers used advanced microscopy to examine changes in marked RNAs in time and location at synapses, and a sequencing technique to characterise ‘marked’ RNAs in brain tissue from the hippocampus, a region of the brain very important for memory formation.
Dr Knight said: “In this new study, we are able to gain a new understanding of the genomic mechanisms which regulate how nerve cells communicate at synapses. These genomic mechanisms involve methyl groups being put on RNA messages and importantly taken off when a synapse is active.”
Inpatient rehab1 week ago
QEF appeal hits £1million milestone
Interviews4 weeks ago
Emilia Clarke’s SameYou – a catalyst for change
Insight1 week ago
How housing design can improve quality of life
News4 weeks ago
Robot with ‘potential to redefine neurorehab’ unveiled by Fourier
News4 weeks ago
Webinar to assess the Rehabilitation Prescription
News4 weeks ago
Sexual trauma ‘could lead to neurological conditions’
News4 weeks ago
Zen Koh takes on global change-maker role
Brain injury3 weeks ago
Blood test set to transform detection of brain damage after head injury